Physician profile
Sarah Ann Beeson
NPI 1114362639
$1,381.23
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $492 · 2020: $471 · 2021: $11.93 · 2022: $384 · 2023: $22.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $353.67 | 2019-2022 | |
| Abbvie INC. | $163.01 | 2019-2023 | Qulipta |
| Lilly USA, LLC | $150.22 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $136.60 | 2022 | |
| Glaxosmithkline, LLC. | $110.59 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $85.60 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.90 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.13 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.64 | 2022 | |
| Astellas Pharma US INC | $37.02 | 2019-2020 | |
| Dexcom, INC. | $36.88 | 2022 | |
| Axsome Therapeutics, INC. | $19.20 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.13 | 2019 | |
| Axonics, INC. | $15.88 | 2022 | |
| Dermira, INC. | $13.80 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $13.40 | 2020 | |
| Sanofi Pasteur INC. | $12.59 | 2020 | |
| Merck Sharp & Dohme LLC | $12.58 | 2020 | |
| Abbott Laboratories | $12.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Beeson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.